Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/23483
Type
Papers presented at eventsCopyright
Open access
Sustainable Development Goals
03 Saúde e Bem-EstarCollections
Metadata
Show full item record
EVALUATION OF RESULTS OF ASSOCIATION OF THE T.CRUZI CHEMOTHERAPIC BENZNIDAZOLE WITH OTHERS DRUGS (NIFURTIMOX, CETOCONAZOLE) IN THE TREATMENT OF THE EXPERIMENTAL CHAGAS DISEASE
Affilliation
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Laboratório de Chagas Experimental Autoimunidade e Imunologia Celular. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Laboratório de Chagas Experimental Autoimunidade e Imunologia Celular. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Laboratório de Chagas Experimental Autoimunidade e Imunologia Celular. Salvador, BA, Brasil.
Abstract
Introduction: Treatment of Chagas disease, determined by infection with Trypanosoma cruzi has been a challenge due to the different susceptibility of the parasite strains, characterized into different biological types or Biodemes. It has been shown that the Benznidazole (BZ) is the drug of choice for the treatment in humans but the results are irregular in patients of different endemic areas. Experimental data have shown a high resistance of the strains of Biodeme type III (T. cruzi I), and irregular results in the
treatment of infections with Type II strains (T. cruzi II). The same results were obtained in the treatment with Nifurtimox (NF), in respect to the resistance of different strains. Other drugs in clinical use for different diseases have been assayed experimentally as the case of the Cetoconazole (Ceto). Probably the association of different drugs could improve the results of treatment in humans. Combinations of drugs may shorten the period of treatment and diminish the collateral toxic effects.
Share